AstraZeneca and Ionis reported today that Wainua underwhelmed in a Phase 3 heart disease trial that could've accelerated its shot to become a blockbuster drug. The UK pharma's stock dipped by as much as 10%, which is one of the few instances it's dropped significantly over the past 10 years due to a clinical trial failure. Elizabeth Cairns has the details.